covid-19
- North America > United States > New York (0.04)
- Asia > China > Hubei Province > Wuhan (0.04)
- North America > United States > North Carolina > Orange County > Chapel Hill (0.04)
- Europe (0.04)
- Research Report > New Finding (1.00)
- Research Report > Experimental Study (1.00)
- North America > United States (0.14)
- Europe > Italy (0.04)
- Asia > Nepal (0.04)
- Information Technology > Security & Privacy (1.00)
- Health & Medicine > Nuclear Medicine (1.00)
- Health & Medicine > Diagnostic Medicine > Imaging (1.00)
- Health & Medicine > Therapeutic Area > Infections and Infectious Diseases (0.72)
- North America > United States > Washington > King County > Seattle (0.04)
- North America > Canada (0.04)
- Europe > United Kingdom > England > Tyne and Wear > Newcastle (0.04)
- (2 more...)
- Asia > China (0.04)
- North America > United States > New Mexico > Los Alamos County > Los Alamos (0.04)
- North America > United States > Texas (0.04)
- (6 more...)
- Health & Medicine > Therapeutic Area > Infections and Infectious Diseases (1.00)
- Health & Medicine > Therapeutic Area > Immunology (1.00)
- Health & Medicine > Epidemiology (1.00)
- Government (0.93)
- Europe > United Kingdom > England > Oxfordshire > Oxford (0.14)
- North America > United States > Virginia (0.04)
- North America > United States > Ohio (0.04)
- (5 more...)
- Europe > United Kingdom > England > Oxfordshire > Oxford (0.29)
- North America > United States (0.14)
- Asia > China (0.04)
- (5 more...)
- North America > United States (0.47)
- Europe > France (0.05)
- Europe > Portugal (0.05)
- (34 more...)
- Health & Medicine > Therapeutic Area > Infections and Infectious Diseases (1.00)
- Health & Medicine > Therapeutic Area > Immunology (1.00)
- Health & Medicine > Epidemiology (1.00)
- Health & Medicine > Public Health (0.96)
CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models
The novel nature of SARS-CoV-2 calls for the development of efficient de novo drug design approaches. In this study, we propose an end-to-end framework, named CogMol (Controlled Generation of Molecules), for designing new drug-like small molecules targeting novel viral proteins with high affinity and off-target selectivity. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme that uses guidance from attribute predictors trained on latent features. To generate novel and optimal drug-like molecules for unseen viral targets, CogMol leverages a protein-molecule binding affinity predictor that is trained using SMILES VAE embeddings and protein sequence embeddings learned unsupervised from a large corpus. We applied the CogMol framework to three SARS-CoV-2 target proteins: main protease, receptor-binding domain of the spike protein, and non-structural protein 9 replicase. The generated candidates are novel at both the molecular and chemical scaffold levels when compared to the training data. CogMol also includes insilico screening for assessing toxicity of parent molecules and their metabolites with a multi-task toxicity classifier, synthetic feasibility with a chemical retrosynthesis predictor, and target structure binding with docking simulations.
Pop music has gotten sadder over the last 50 years
Analysis of 20,186 songs from the Billboard Top 100 indicates that the lyrics are also more simple. Breakthroughs, discoveries, and DIY tips sent every weekday. Debating the merits of today's popular music versus the hits of the past is largely a matter of taste. But regardless of your opinion on the subject, one thing is clear: pop music is objectively darker and more stressful than ever. The compelling statistics are laid out in a study by University of Vienna psychologists recently published in the journal .
- Europe > Austria > Vienna (0.25)
- North America > United States (0.05)
- Europe > Sweden (0.05)
- (2 more...)
- Media > Music (1.00)
- Leisure & Entertainment (1.00)
Use of Retrieval-Augmented Large Language Model Agent for Long-Form COVID-19 Fact-Checking
Huang, Jingyi, Yang, Yuyi, Ji, Mengmeng, Alba, Charles, Zhang, Sheng, An, Ruopeng
The COVID-19 infodemic calls for scalable fact-checking solutions that handle long-form misinformation with accuracy and reliability. This study presents SAFE (system for accurate fact extraction and evaluation), an agent system that combines large language models with retrieval-augmented generation (RAG) to improve automated fact-checking of long-form COVID-19 misinformation. SAFE includes two agents - one for claim extraction and another for claim verification using LOTR-RAG, which leverages a 130,000-document COVID-19 research corpus. An enhanced variant, SAFE (LOTR-RAG + SRAG), incorporates Self-RAG to refine retrieval via query rewriting. We evaluated both systems on 50 fake news articles (2-17 pages) containing 246 annotated claims (M = 4.922, SD = 3.186), labeled as true (14.1%), partly true (14.4%), false (27.0%), partly false (2.2%), and misleading (21.0%) by public health professionals. SAFE systems significantly outperformed baseline LLMs in all metrics (p < 0.001). For consistency (0-1 scale), SAFE (LOTR-RAG) scored 0.629, exceeding both SAFE (+SRAG) (0.577) and the baseline (0.279). In subjective evaluations (0-4 Likert scale), SAFE (LOTR-RAG) also achieved the highest average ratings in usefulness (3.640), clearness (3.800), and authenticity (3.526). Adding SRAG slightly reduced overall performance, except for a minor gain in clearness. SAFE demonstrates robust improvements in long-form COVID-19 fact-checking by addressing LLM limitations in consistency and explainability. The core LOTR-RAG design proved more effective than its SRAG-augmented variant, offering a strong foundation for scalable misinformation mitigation.
- North America > United States (0.47)
- Asia > China > Shanghai > Shanghai (0.04)
- North America > Canada (0.04)
- Research Report > New Finding (1.00)
- Research Report > Experimental Study (1.00)
- Health & Medicine > Therapeutic Area > Infections and Infectious Diseases (1.00)
- Health & Medicine > Therapeutic Area > Immunology (1.00)
- Health & Medicine > Epidemiology (1.00)